Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPER-4: once-weekly MET097 in adults with overweight or obesity
2025-523974-18-00Phase 3Authorised
- Sponsor
- Metsera
- Start
- Apr 2026
- Modality
- Peptides
- Countries
- 11
01
Overview
Phase 3, randomised trial in obesity and Overweight comparing MET097 once weekly with Matching placebo once weekly (2 arms). Planned start Apr 2026; status: authorised.
02
Drugs
PF-08653944
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2025-523974-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523974-18-00.